Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/3/2025

Management of 2cm Basal Cell Carcinoma on the Cheek

Introduction to High-Risk Lesions

  • The National Comprehensive Cancer Network (NCCN) guidelines state that any BCC in the H-zone (central face, including cheeks) constitutes high risk independent of size 1
  • Low-risk primary BCC is defined as well-defined lesions <2cm, making this 2cm lesion at the upper boundary or potentially beyond low-risk classification 2

Treatment Algorithm for High-Risk Lesions

  • The American Academy of Dermatology recommends Mohs micrographic surgery (MMS) for high-risk BCCs, as it achieves superior cure rates with 5-year recurrence rates of 1% for primary BCC 1, 3
  • MMS provides complete margin control through en face horizontal sectioning, allowing examination of 100% of peripheral and deep margins, critical for facial locations where subclinical extension is unpredictable 3
  • MMS maximizes tissue preservation, essential on the cheek where cosmetic and functional outcomes matter 3, 4

Second-Line Treatment Options

  • For high-risk tumors where MMS is unavailable, standard excision with wider margins (5-10mm) is suggested, though even these may be insufficient without complete margin control 4, 5
  • Standard excision must include complete histologic margin assessment with verification of negative margins before closure 1, 3

Critical Considerations

  • The American Academy of Dermatology guidelines explicitly state that 4mm margins are for low-risk primary BCC only, and this lesion does not meet low-risk criteria due to its facial location and 2cm size 1, 2
  • Positive margins carry a 26.8% recurrence risk, versus 5.9% with negative margins 1, 3
  • Facial BCCs have higher recurrence rates, with 12.2% recurrence at 10 years, and 56% of recurrences identified beyond 5 years 1

Pitfalls to Avoid

  • Do not treat facial BCCs as low-risk, as location automatically elevates risk regardless of clinical appearance 1, 2
  • Do not use curettage and electrodesiccation for facial lesions, as they show 47% residual tumor rates and 19-27% recurrence 2, 4
  • Do not assume well-defined borders mean limited subclinical extension, as BCCs characteristically show asymmetrical subclinical extension beyond visible margins 1, 3

REFERENCES

1

guidelines of care for the management of basal cell carcinoma. [LINK]

Journal of the American Academy of Dermatology, 2018

2

Electrodesiccation and Curettage for Basal Cell Carcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

guidelines of care for the management of basal cell carcinoma. [LINK]

Journal of the American Academy of Dermatology, 2018

5

Mohs Surgery for Infiltrative Basal Cell Carcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025